What is a white-label biotechnology dashboard?
A white-label biotechnology dashboard, in the strict reseller sense, does not exist as a market category. Biotechnology and pharmaceutical operations are served by highly specialist, often regulatory-validated software: LIMS (Laboratory Information Management Systems) for sample tracking and test results, ELN (Electronic Lab Notebooks) for experiment records, and bioinformatics platforms for sequence and assay data. These are systems organizations deploy or subscribe to under their own contracts — not products a reseller licenses, brands, and distributes. This distinction matters enormously: the regulated-data layer in a biotech operation is governed by FDA 21 CFR Part 11 (electronic records and signatures), GxP principles, and where clinical data is involved, HIPAA. A generic horizontal portal cannot make you compliant with these requirements, and no amount of branding changes that fact.
What a general white-label platform can realistically cover is the non-regulated business-operations layer around validated lab systems: R&D pipeline status and project management, grant and funding milestone tracking, equipment calendars, budget burn-rate dashboards, and investor and board reporting. SuiteDash (SU1TE wholesale at $14/$34/$69 per account/month), GoHighLevel ($297/$497/month), or open-source BI tools like Grafana and Metabase can host branded dashboards for these operational metrics — they cannot and should not host regulated experimental data.
For the regulated core — sample chain-of-custody, validated experiment records, audit trails with e-signatures, and regulatory submission data — the honest path is deploying a validated LIMS or ELN, priced at enterprise levels and gated by compliance validation status. Any vendor that claims their generic dashboard substitutes for a validated LIMS is making a claim that should raise immediate red flags from a regulatory standpoint.
Who uses this
Buyers searching for a 'biotechnology dashboard' in the white-label sense are typically: biotech startup operators who want a branded investor-facing R&D progress dashboard; CROs (contract research organizations) building client-reporting portals over non-regulated project data; lab IT teams looking for a business-intelligence layer to aggregate operational metrics from multiple validated systems; and technology consultants building bespoke ops-layer dashboards for biotech clients who already have validated LIMS/ELN in place. None of these use cases require — or should use — a validated LIMS replacement.
No niche white-label biotech dashboard reseller product exists. The specialist software market for regulated lab operations is served by LIMS, ELN, and bioinformatics platforms — often Part-11-validated and enterprise-priced (sales-gated; verify current pricing directly with vendors). For non-regulated operational dashboards, horizontal platforms are the closest option: SuiteDash SU1TE at $14–$69/account/month, GoHighLevel at $297–$497/month, or self-hosted open-source BI (Grafana, Metabase) for near-zero license cost. The load-bearing constraint in this vertical is always compliance scope: regulated lab data belongs in validated systems, period.
Quick verdict
There is no white-label biotechnology dashboard market, and the honest reason is that regulated lab data must live in validated software (LIMS/ELN) — a generic portal cannot substitute. What is buildable and sensible is a branded operational-layer dashboard covering non-regulated business metrics: pipeline, samples at a high level, budget, and investor reporting. A custom build at $13K–$25K covers that scope well; a horizontal portal at $14–$497/month works for lighter reporting needs.
Go white-label if
You only need a branded reporting overlay for non-regulated ops metrics — R&D pipeline, budget, investor updates — on top of validated lab systems you already run, with a budget under $10K and a timeline under 30 days.
Go custom if
You need a bespoke R&D-ops dashboard integrating data from multiple validated systems, with precise pipeline-stage logic, investor reporting workflows, and full data ownership — while keeping all regulated lab records in validated LIMS/ELN.
White-label vs off-the-shelf vs custom
The three real ways to run a Biotechnology Dashboard. The highlighted cell wins each row.
| Aspect | White-label | Off-the-shelf SaaS | Custom build |
|---|---|---|---|
| Time to launch | 1–3 weeks (ops-reporting portal config) | Immediate (subscribe to validated LIMS/ELN; not rebrandable) | 6–10 weeks |
| Upfront cost | $0–$5,000 (config) | Enterprise pricing; typically $10,000+ implementation (verify) | $13,000–$25,000 fixed |
| Monthly fees | $14–$497/mo horizontal portal (validated systems billed separately) | Enterprise LIMS/ELN; sales-gated (verify) | ~$100/mo hosting after build |
| Branding depth | Logo, colors, domain — no vendor branding on $297+ tier | Vendor-branded; not rebrandable | Fully bespoke; zero vendor trace |
| Feature flexibility | Generic ops reporting only — no validated lab or audit-trail features | Validated lab workflows, audit trails, e-signatures — the regulated core | Any non-regulated ops logic; integrations with validated systems |
| Code and data ownership | No code ownership; data held by platform vendor | No code ownership; data held by LIMS/ELN vendor | 100% code and ops-data ownership |
| Regulatory compliance | Not applicable — generic portal cannot provide 21 CFR Part 11 compliance | Validated for Part 11/GxP where applicable — the purpose of these systems | Not a validated LIMS replacement — scope to non-regulated ops only |
| Exit options | Data export per vendor terms; ask before signing | Vendor-controlled; migration can be costly and complex for validated systems | Full ops-data ownership; migrate ops layer at any time |
Swipe the table sideways to see all three paths.
Features a Biotechnology Dashboard actually needs
R&D pipeline and project status tracking
Must-haveHigh-level view of all active research programs, stage-gate progress, current phase (discovery, preclinical, clinical), and milestone completion status for each project.
Sample and specimen inventory overview
Must-haveNon-regulated inventory view of sample counts, storage locations, and status across projects — integrated with or exported from validated LIMS, not replacing it.
Assay and experiment result aggregation
Must-haveDashboard-level visualization of experiment outcomes and trend data pulled from validated systems — summary metrics for project teams, not the validated records themselves.
Grant and funding milestone tracking
Must-haveTimeline and deliverable tracking for each active grant or funding round, with milestone completion status and reporting deadlines for each funder.
Budget and burn-rate dashboards
Must-havePer-project and organization-wide budget allocation, actual spend, and burn-rate projections — the financial operational layer for R&D programs.
Equipment and instrument status tracking
Must-haveOperational calendar for lab equipment with maintenance schedules, calibration due dates, and current availability — non-regulated scheduling layer.
Team and lab-resource allocation
Must-haveScientist and team assignments across projects, with workload visibility and time-allocation tracking for resource planning.
Investor and board reporting dashboards
Must-haveBranded executive-view dashboards showing pipeline progress, key data readouts, and financial burn for investor updates, board decks, and fundraising materials.
Role-based access with strict scoping
Must-havePermission tiers for principal investigators, researchers, QA reviewers, finance, and board/investor views — controlling exactly what each group can see and cannot see.
Audit trail and activity logging for ops layer
EdgeActivity log for all dashboard-level actions — who viewed or exported which reports — separate from the validated audit trails in LIMS/ELN.
Data export for investor and regulatory reporting
EdgeOne-click export of pipeline summaries, budget reports, and milestone status to PDF or CSV formatted for investor decks or regulatory-submission supporting materials.
The real cost of a white-label Biotechnology Dashboard
Sticker price is never the whole story. Here is what you actually pay.
Setup fee
$0–$5,000
one-time onboarding
Monthly
$14–$497/mo
recurring, forever
Custom (one-time)
$13,000–$25,000 one-time
you own it
Uncommon in this vertical. Horizontal portal platforms charge flat fees; validated LIMS/ELN is enterprise-priced separately.
Hidden costs to budget for
Validated LIMS and ELN — the regulated-data layer
The compliance cost is not in the dashboard — it is in the validated lab software that the dashboard sits on top of. Enterprise LIMS and ELN are sales-gated, implementation-heavy, and often carry validation consulting costs on top of the license. A generic ops dashboard does not replace these systems, and failing to budget for them is the most dangerous gap in biotech software planning.
21 CFR Part 11 validation and compliance consulting
Any system that stores regulated electronic records — experiment data, e-signatures, audit trails — in an FDA-regulated environment requires validation effort (IQ/OQ/PQ documentation) and may need external consulting to execute. This is a separate, often six-figure, cost line from any dashboard platform. A branded ops dashboard does not trigger Part 11 requirements; but the systems it integrates with likely do.
Per-seat and per-account growth on horizontal platforms
SuiteDash SU1TE wholesale runs $14/$34/$69 per client account per month. GoHighLevel is flat at $297–$497/month with unlimited sub-accounts — more predictable for multi-team organizations. As headcount scales, per-seat variants compound quickly.
Integration development with validated systems
Pulling summary data from a validated LIMS or ELN into a business dashboard requires API or export integration — which the dashboard platform does not include. Building and maintaining that integration layer is a recurring development cost, not a one-time setup.
Data export at termination
Ops-layer data on a horizontal portal may be difficult or costly to export cleanly. Verbatim question to ask: 'At termination, in what format, on what timeline, and at what cost can I export all of my data — including pipeline records, budget data, and reporting history?'
3-year cost reality
A horizontal portal at $297–$497/month for the ops layer costs $10,700–$17,900 over 3 years, and cannot provide validated lab functionality. A custom ops dashboard at $13K–$25K one-time plus ~$100/month hosting totals $16,600–$28,600 over 3 years — with full pipeline-stage logic, multi-system integration, and data ownership. The critical caveat in biotech: both cost paths are on top of validated LIMS/ELN costs, which are always larger and non-negotiable for regulated programs.
White-label launch roadmap
Before any dashboard platform decision, the first question in biotech is compliance scope: which data in your operation is regulated (Part 11, GxP, HIPAA), and which is non-regulated ops? The dashboard conversation only applies to the non-regulated layer.
Compliance scope definition
1–2 weeksMap your data types to regulatory requirements: which records require 21 CFR Part 11 validated systems (experiment data, e-signatures, audit trails), which are clinical/HIPAA-covered, and which are non-regulated ops (pipeline, budget, investor updates). The dashboard strategy only applies to the non-regulated ops category.
Watch out: This step is non-negotiable in regulated biotech. Skipping it and building or configuring a dashboard without clarity on data scope risks placing regulated data in non-validated systems — a serious FDA compliance failure. Involve your QA team or regulatory counsel before selecting any platform.
Validated system inventory
1 weekConfirm which validated LIMS/ELN/bioinformatics systems are in place or need to be deployed, and identify what data APIs or export formats they offer for integration into a business dashboard. The ops dashboard is a consumer of these systems, not a replacement.
Watch out: Validated system API access is often limited or non-standard — some LIMS expose REST APIs, others only CSV or flat-file exports. Integration approach depends on what your validated systems actually support.
Ops dashboard platform decision and configuration
1–3 weeksSelect the ops dashboard approach — horizontal portal for a fast branded shell, open-source BI (Grafana/Metabase) for more flexible visualization, or custom build for bespoke pipeline logic. Configure branding, data connections from validated systems, report templates, and role-based access tiers.
Watch out: Custom logic for pipeline stage-gate definitions, grant milestone rules, and investor-report formatting cannot be templated from a generic portal — this work is always custom regardless of the display platform.
Integration and data validation
1–2 weeksConnect the ops dashboard to your validated systems via API or export pipeline. Validate that summary data appearing in the dashboard matches source records, and confirm audit logging is in place for all ops-layer access.
Watch out: Data aggregation from multiple validated systems (LIMS, ELN, bioinformatics, financial) often surfaces inconsistencies in naming conventions, units, and time zones — expect at least a week of data-cleaning work before summaries are reliable.
Role access audit and launch
1 weekConduct a final review of access permissions — confirm that investor-facing and public views do not expose any regulated or confidential data. Soft launch with internal users before any external stakeholder access.
Watch out: Investor dashboards that inadvertently surface preliminary or unvalidated experimental data can create IP and regulatory issues — review data exposure with legal and QA before external rollout.
Vendor red flags & what to ask
Before you sign, pressure-test every vendor with these. The wrong answer here costs you later.
Claims to provide 21 CFR Part 11 compliance without validated system status
FDA 21 CFR Part 11 compliance for electronic records requires specific validated software (IQ/OQ/PQ documentation, audit trails, e-signature controls). A generic dashboard platform — white-label or otherwise — cannot simply claim Part 11 compliance through configuration. This is a regulatory red flag, not a marketing distinction.
Ask the vendor: “Is any part of my experimental or assay data subject to 21 CFR Part 11 or GxP? If so, that data belongs in validated software — what exactly is your validation status, IQ/OQ/PQ documentation, and FDA inspection history?”
Positions dashboard as a LIMS or ELN replacement
A business ops dashboard cannot perform the chain-of-custody, audit-trail, and e-signature functions of a validated LIMS — and claiming it can is either regulatory ignorance or misdirection. Any vendor who frames their dashboard as eliminating the need for a LIMS should be disqualified immediately.
Ask the vendor: “Does this platform maintain validated chain-of-custody, audit trails, and e-signature capabilities for regulated experiment records — or is it scoped to non-regulated operational and reporting data only?”
No clear data-export provisions
Biotech R&D pipeline data, budget records, and investor reporting history are operationally critical. If a vendor cannot specify export terms in the contract, migration away is a crisis.
Ask the vendor: “At termination, in what format, on what timeline, and at what cost can I export all of my pipeline, budget, and reporting data — including all historical records? Put it in the contract.”
Per-seat pricing without a growth cap
Research teams grow rapidly as programs advance — headcount can double between Series A and Series B. Uncapped per-seat pricing on the ops dashboard becomes a material cost as team size grows.
Ask the vendor: “How does pricing scale with team headcount and number of active programs, and is there a price-cap or enterprise tier that provides predictability as we scale?”
Roadmap dependency for compliance-adjacent features
If the dashboard vendor's roadmap determines whether audit-log, role-restriction, or e-signature features are available, and those features are needed for your ops layer, a vendor pivot or deprioritization can leave your compliance program dependent on a feature that disappears.
Ask the vendor: “What happens to the audit-log and access-control features my team relies on if you deprioritize or remove them from the product roadmap — do I have contractual guarantees on feature availability?”
How far can you actually customize it?
Typical branding
- Logo and brand colors across the ops-dashboard UI
- Custom domain with no vendor branding visible
- Branded login page and email notifications
- Branded investor and board reporting templates
- White-label client portal (no 'Powered by' on $297+ GoHighLevel or SuiteDash wholesale accounts)
Typical limits
- Pipeline stage-gate logic and grant milestone rules are generic — you cannot define biotech-specific stage definitions without developer customization
- No validated data handling — the portal is not equipped for regulated experimental records, audit trails, or e-signature workflows
- Integration with validated LIMS/ELN systems is not included — connecting your validated data to the dashboard is always custom development
- Source code and database are inaccessible — you are locked into the vendor's data model
- Product roadmap is vendor-driven; biotech-specific features may not be prioritized
Custom unlocks
- Bespoke R&D pipeline logic — define your own stage-gate criteria, go/no-go decision frameworks, and program phase transitions specific to your therapeutic area
- Multi-source integration with validated systems — pull summary data from your LIMS, ELN, and bioinformatics platforms through APIs or export pipelines into a unified ops view
- Investor and board reporting templates built to your exact narrative and metric definitions — not generic charts, but purpose-designed executive communications
- Grant and milestone tracking with funder-specific reporting formats and deadline alert automation
- Strict data-segmentation controls between investor-facing views and internal analyst-grade views — ensuring preliminary or unvalidated data never surfaces in external reports
- Full source code and ops-data ownership — all pipeline, budget, and reporting history in your own infrastructure, independent of any vendor
Which path fits you?
Biotech startup in pre-clinical stage with validated systems already deployed
White-label fitsYou have a LIMS and ELN in place for regulated data and need a branded investor-facing pipeline and budget dashboard. A horizontal portal configured as a reporting shell delivers this in 1–3 weeks for under $5,000 — no custom build needed.
CRO building client-reporting portals for pharma sponsors
White-label fitsYou are a contract research organization that wants a branded portal for each sponsor client showing non-regulated project status, sample milestones, and study timelines. A horizontal white-label portal at $14–$69/account/month delivers the branded reporting layer.
Biotech platform company integrating data from multiple validated systems
Custom fitsYou operate multiple programs across LIMS, ELN, and bioinformatics platforms and need a unified ops dashboard that aggregates summary metrics from all systems into a single investor-grade view with bespoke pipeline logic. A custom build is the only path to get the integration depth and pipeline-stage logic you need.
Life sciences IT team building an enterprise R&D ops layer
Custom fitsYou support multiple internal research groups and need a consistent branded ops dashboard that integrates with enterprise-grade validated systems, enforces strict data-segmentation between teams, and produces audit-ready activity logs for the non-regulated layer.
Technology consultant building ops dashboards for biotech clients
Custom fitsYou build bespoke research operations tools for biotech clients who already have validated LIMS/ELN and need the business-intelligence and investor-reporting layer built to their exact specifications with full source-code ownership.
A white-label you actually own
Renting someone else's Biotechnology Dashboardworks until it doesn't. RapidDev builds you a custom, fully-branded platform using AI-accelerated development — delivered in weeks, and yours to keep with zero recurring platform fees.
Discovery call (free)
30 minWe map exactly what your Biotechnology Dashboard needs — the features white-label vendors gate behind upgrades, your branding, integrations, and users. You get a scoped, fixed-price quote within 48 hours.
AI-accelerated build
6–10 weeksOur engineers use Claude Code, Lovable, and custom AI tooling to build 3–5x faster than traditional agencies. You review progress in a live staging environment every week — never a black box.
Launch + handoff
1 weekWe deploy to your infrastructure, hand over the GitHub repo, wire up CI/CD, and walk your team through the codebase. You own 100% of it — no per-seat fees, no vendor lock-in.
What you get
Timeline
6–10 weeks
Investment
$13K–$25K fixed
Breakeven
Vs a $497/month horizontal portal, a custom build saves ~$6,000/year in platform fees alone — breakeven in roughly 26–50 months. More meaningfully: a custom build delivers the pipeline-stage logic and multi-system integration that a portal platform cannot provide at any price, while keeping regulated lab data correctly in validated LIMS/ELN systems where it belongs.
30-min call. Fixed-price quote within 48 hours. No commitment.
Frequently asked questions
How much does a white-label biotechnology dashboard cost?
No dedicated white-label biotech dashboard product exists for resellers. For a non-regulated ops reporting layer using a horizontal portal, expect $0–$5,000 setup and $14–$497/month. Validated LIMS and ELN software for regulated lab data is enterprise-priced separately — sales-gated, typically much higher. A custom ops dashboard runs $13,000–$25,000 one-time plus ~$100/month hosting. The dominant cost in biotech is always the validated lab-software layer, not the ops dashboard on top of it.
How fast can I launch a branded biotechnology ops dashboard?
A horizontal portal configured as an R&D reporting shell takes 1–3 weeks. The real constraint is often the integration work to pull data from your validated LIMS/ELN systems into the dashboard — that connection layer typically adds 1–2 weeks of development work regardless of platform. A full custom build runs 6–10 weeks. The compliance-scope definition (which data is regulated, which is ops) should happen before any platform configuration starts.
Can a white-label dashboard replace a LIMS or ELN for FDA-regulated data?
No. This is the most important answer on this page. FDA 21 CFR Part 11 compliance for electronic records requires specifically validated software with documented IQ/OQ/PQ, audit trails, and e-signature controls. A generic dashboard — white-label or custom — cannot substitute for a validated LIMS or ELN. Regulated experimental data belongs in validated systems. A dashboard is appropriate only for the non-regulated ops layer: pipeline, budget, resource allocation, and investor reporting.
Do I own my data with a biotechnology dashboard?
With a horizontal portal, you possess your data while the contract is active but the database stays with the vendor — you typically get dashboard-level exports, not a portable ops database. A custom build gives you full ownership of all ops-layer data. Note that your regulated lab data ownership is governed separately by your LIMS/ELN vendor contracts — those terms should always be reviewed carefully given the compliance implications of biotech data migration.
What does '21 CFR Part 11' mean for my dashboard decision?
21 CFR Part 11 is the FDA regulation governing electronic records and electronic signatures in regulated industries. Systems that store experiment records, batch records, or other regulated data for FDA-regulated programs must comply — meaning the software must be validated, maintain audit trails, and support compliant e-signatures. A business ops dashboard (pipeline status, budget, investor reports) does not typically trigger Part 11 requirements. Your LIMS, ELN, and any system storing assay results or manufacturing batch data does. Scope your dashboard to non-regulated data and you are outside Part 11 requirements.
White-label portal vs custom build — what is the real cost difference?
Over 3 years, a horizontal portal at $497/month totals ~$17,900 in platform fees — but it cannot execute biotech pipeline logic or integrate with LIMS/ELN systems without additional custom development. A custom build at $13,000–$25,000 one-time plus ~$3,600 hosting totals $16,600–$28,600 with full integration, pipeline logic, and data ownership. The cost difference is modest; the capability difference in biotech is significant — custom delivers the multi-system integration and bespoke pipeline definitions that a generic portal cannot.
Can RapidDev build a custom biotechnology ops dashboard?
Yes. RapidDev builds custom R&D operations dashboards for biotech clients in 6–10 weeks at $13K–$25K fixed price, scoped to the non-regulated ops layer: pipeline stage-gate tracking, budget and burn-rate dashboards, grant milestone management, equipment scheduling, investor reporting templates, and integration with validated LIMS/ELN systems via API or export. Regulated lab data always stays in validated systems — that is a firm scope boundary. We offer a free scoping call to map your data architecture and compliance scope before any build commitment.
What regulatory compliance does a biotech dashboard need to address?
An ops dashboard covering non-regulated data (pipeline, budget, investor reporting) does not itself require 21 CFR Part 11 validation. However: all data you display must come from validated sources via secure integration; access controls must prevent unauthorized viewing of sensitive R&D data; activity logging should track who accessed or exported what and when. If any clinical patient data is ever surfaced in the dashboard, HIPAA applies immediately. Confirm with your regulatory and legal teams which data categories are in scope for your specific programs before finalizing dashboard architecture.
Own your Biotechnology Dashboard, don't rent it
- Delivered in 6–10 weeks
- You own 100% of the code
- No monthly platform fees
30-min call. No commitment.